Hansa Biopharma and German payer head association agree on r

/PRNewswire/ -- Hansa Biopharma AB, "Hansa" (Nasdaq Stockholm: HNSA), the pioneer in enzyme technology for rare immunological conditions, today announces...

Related Keywords

Sweden , Germany , Stockholm , Netherlands , Finland , France , Jordan , Greece , German , Hansa Biopharma , Prnewswire Hansa Biopharma , Klaus Sindahl , Katja Margell , National Association Of Statutory Health Insurance Funds , European Union , European Medicines Agency , European Medicines Agency Ema Priority , Head Of Corporate Communications , National Association , Statutory Health Insurance Funds , Nasdaq Stockholm , Medicines Market Reorganization Act , Human Leukocyte Antigens , European Marketing Authorization , End Stage Renal Disease , Product Characteristicsfound , Product Characteristics , Englj Med , Hansa Biopharma Ab ,